Skip to main content
SpringerLink
Log in

Molecular Pathogenesis of Multiple Myeloma: Chromosomal Aberrations, Changes in Gene Expression, Cytokine Networks, and the Bone Marrow Microenvironment

  • Chapter
  • First Online:
Multiple Myeloma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 183))

Abstract

This chapter focuses on two aspects of myeloma pathogenesis: (1) chromosomal aberrations and resulting changes in gene and protein expression with a special focus on growth and survival factors of malignant (and normal) plasma cells and (2) the remodeling of the bone marrow microenvironment induced by accumulating myeloma cells. We begin this chapter with a discussion of normal plasma cell generation, their survival, and a novel class of inhibitory factors. This is crucial for the understanding of multiple myeloma, as several abilities attributed to malignant plasma cells are already present in their normal counterpart, especially the production of survival factors and interaction with the bone marrow microenvironment (niche). The chapter closes with a new model of pathogenesis of myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100(6):2195–2202

    PubMed  CAS  Google Scholar 

  • Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104(8):2484–2491

    PubMed  CAS  Google Scholar 

  • Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E (2004) Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol 27(1):8–13

    PubMed  Google Scholar 

  • Allen CD, Okada T, Cyster JG (2007a) Germinal-center organization and cellular dynamics. Immunity 27(2):190–202

    PubMed  CAS  Google Scholar 

  • Allen SJ, Crown SE, Handel TM (2007b) Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 25:787–820

    PubMed  CAS  Google Scholar 

  • Andersen TL, Soe K, Sondergaard TE, Plesner T, Delaisse JM (2010) Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells. Br J Haematol 148(4):551–561

    Google Scholar 

  • Andersen TL, Sondergaard TE, Skorzynska KE, Dagnaes-Hansen F, Plesner TL, Hauge EM, Plesner T, Delaisse JM (2009) A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 174(1):239–247

    PubMed  CAS  Google Scholar 

  • Arce S, Luger E, Muehlinghaus G, Cassese G, Hauser A, Horst A, Lehnert K, Odendahl M, Honemann D, Heller KD, Kleinschmidt H, Berek C, Dorner T, Krenn V, Hiepe F, Bargou R, Radbruch A, Manz RA (2004) CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J Leukoc Biol 75(6):1022–1028

    PubMed  CAS  Google Scholar 

  • Arora T, Jelinek DF (1998) Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression. J Biol Chem 273(19):11799–11805

    PubMed  CAS  Google Scholar 

  • Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F, Rapp MJ, Talmant P, Trimoreau F, Jaccard A, Harousseau JL, Bataille R (1998) High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 58(24):5640–5645

    PubMed  CAS  Google Scholar 

  • Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C (2007) Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 109(8):3489–3495

    PubMed  CAS  Google Scholar 

  • Avet-Loiseau H, Moreau P, Mathiot C, Charbonnel C, Caillot D, Facon T, Attal M, Benboubker L, Hulin C, Marit G, Minvielle S, Harousseau JL (2009) Induction with velcadeÒ/dexamethasone partially overcomes the poor prognosis of t(4;14), but not that of del(17p), in young patients with multiple myeloma. ASH Annu Meeting Abstr 114(22):957

    Google Scholar 

  • Aviles A, Nambo MJ, Neri N, Castaneda C, Cleto S, Huerta-Guzman J (2007) Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 24(2):227–230

    PubMed  CAS  Google Scholar 

  • Barclay AN, Wright GJ, Brooke G, Brown MH (2002) CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol 23(6):285–290

    PubMed  CAS  Google Scholar 

  • Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K (1985) Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 66(2):338–341

    PubMed  CAS  Google Scholar 

  • Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J, Shaughnessy JD, Jagannath S, Bolejack V, Gurley J, Hoering A, Vesole D, Desikan R, Siegel D, Mehta J, Singhal S, Munshi NC, Dhodapkar M, Jenkins B, Attal M, Harousseau JL, Crowley J (2006) Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 135(2):158–164

    PubMed  Google Scholar 

  • Barlogie B, Anaissie EJ, van Rhee F, Shaughnessy JD Jr, Haessler J, Pineda-Roman M, Hollmig K, Epstein J, Crowley JJ (2008) Total therapy (TT) for myeloma (MM)–10% cure rate with TT1 suggested by >10 year continuous complete remission (CCR): bortezomib in TT3 overcomes poor-risk associated with T(4;14) and DelTP53 in TT2. J Clin Oncol (Meeting Abstracts) 26(15):8516

    Google Scholar 

  • Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84(6):2008–2011

    PubMed  CAS  Google Scholar 

  • Bataille R, Chappard D, Marcelli C, Rossi JF, Dessauw P, Baldet P, Sany J, Alexandre C (1990) Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br J Haematol 76(4):484–487

    PubMed  CAS  Google Scholar 

  • Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88(1):62–66

    PubMed  CAS  Google Scholar 

  • Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B (1995) Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 86(2):685–691

    PubMed  CAS  Google Scholar 

  • Batista FD, Harwood NE (2009) The who, how and where of antigen presentation to B cells. Nat Rev Immunol 9(1):15–27

    PubMed  CAS  Google Scholar 

  • Beattie J, Phillips K, Shand JH, Szymanowska M, Flint DJ, Allan GJ (2005) Molecular recognition characteristics in the insulin-like growth factor (IGF)-insulin-like growth factor binding protein-3/5 (IGFBP-3/5) heparin axis. J Mol Endocrinol 34(1):163–175

    PubMed  CAS  Google Scholar 

  • Bergsagel PL, Kuehl WM (2003) Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96–104

    PubMed  CAS  Google Scholar 

  • Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23(26):6333–6338

    PubMed  CAS  Google Scholar 

  • Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106(1):296–303

    PubMed  CAS  Google Scholar 

  • Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Tribalto M, Testa MG (1984) Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br J Haematol 58(4):689–696

    PubMed  CAS  Google Scholar 

  • Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C, Chauhan D, Okawa Y, Munshi NC, Richardson PG, Anderson KC (2008) Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 22(10):1925–1932

    PubMed  CAS  Google Scholar 

  • Calame K (2008) Activation-dependent induction of Blimp-1. Curr Opin Immunol 20(3):259–264

    PubMed  CAS  Google Scholar 

  • Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9(4):313–325

    PubMed  CAS  Google Scholar 

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS, Jove R (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105–115

    PubMed  CAS  Google Scholar 

  • Chang H, Sloan S, Li D, Zhuang L, Yi QL, Chen CI, Reece D, Chun K, Keith SA (2004) The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol 125(1):64–68

    PubMed  Google Scholar 

  • Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC (2003) Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A(8):1544–1552

    PubMed  Google Scholar 

  • Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB (2004) The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10(11):1251–1256

    PubMed  CAS  Google Scholar 

  • Chiecchio L, Protheroe RK, Ibrahim AH, Cheung KL, Rudduck C, Dagrada GP, Cabanas ED, Parker T, Nightingale M, Wechalekar A, Orchard KH, Harrison CJ, Cross NC, Morgan GJ, Ross FM (2006) Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20(9):1610–1617

    PubMed  CAS  Google Scholar 

  • Chng WJ, Winkler JM, Greipp PR, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Ahmann GJ, Henderson K, Blood E, Oken MM, Hulbert A, Wier SA, Santana-Davila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R (2006) Ploidy status rarely changes in myeloma patients at disease progression. Leuk Res 30(3):266–271

    Google Scholar 

  • Cobaleda C, Schebesta A, Delogu A, Busslinger M (2007) Pax5: the guardian of B cell identity and function. Nat Immunol 8(5):463–470

    PubMed  CAS  Google Scholar 

  • Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Reme T, Goldschmidt H, Klein B (2007) Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 178(5):3307–3315

    PubMed  CAS  Google Scholar 

  • Condomines M, Hose D, Reme T, Requirand G, Hundemer M, Schoenhals M, Goldschmidt H, Klein B (2009) Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma. J Immunol 183(2):832–840

    PubMed  CAS  Google Scholar 

  • Condomines M, Veyrune JL, Larroque M, Quittet P, Latry P, Lugagne C, Hertogh C, Kanouni T, Rossi JF, Klein B (2010) Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodepletion in patients with multiple myeloma: a window for adoptive immunotherapy. J Immunol 184(2):1079–1084

    PubMed  CAS  Google Scholar 

  • Cornish J, Callon KE, Coy DH, Jiang NY, Xiao L, Cooper GJ, Reid IR (1997) Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am J Physiol 273(6 Pt 1): E1113–E1120

    PubMed  CAS  Google Scholar 

  • Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, Bourin P (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 21(5):1079–1088

    PubMed  CAS  Google Scholar 

  • Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B (1998) Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol 103(4):1152–1160

    PubMed  CAS  Google Scholar 

  • Costes V, Magen V, Legouffe E, Durand L, Baldet P, Rossi JF, Klein B, Brochier J (1999) The Mi15 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol 30(12):1405–1411

    PubMed  CAS  Google Scholar 

  • Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, Benner A, Raab MS, Theil AC, Moos M, Goldschmidt H, Bartram CR, Jauch A (2005) Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer 44(2):194–203

    PubMed  CAS  Google Scholar 

  • De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B (2000) JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 109(4):823–828

    PubMed  Google Scholar 

  • De Vos J, Couderc G, Tarte K, Jourdan M, Requirand G, Delteil MC, Rossi JF, Mechti N, Klein B (2001) Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 98(3):771–780

    PubMed  Google Scholar 

  • De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestris F (2009) Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. Leuk Res 34(2):243–249

    Google Scholar 

  • Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 26(29):4798–4805

    PubMed  CAS  Google Scholar 

  • Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100(1):194–199

    PubMed  CAS  Google Scholar 

  • Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST (2002) Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood 99(4):1405–1410

    PubMed  CAS  Google Scholar 

  • Descamps G, Wuilleme-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, Collette M, Robillard N, Bataille R, Amiot M (2006) CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol 177(6):4218–4223

    PubMed  CAS  Google Scholar 

  • DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, Kelsoe G, Tedder TF (2008) Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 180(1):361–371

    PubMed  CAS  Google Scholar 

  • Drach J, Schuster J, Nowotny H, Angerler J, Rosenthal F, Fiegl M, Rothermundt C, Gsur A, Jager U, Heinz R (1995) Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55(17):3854–3859

    PubMed  CAS  Google Scholar 

  • Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI (1981) The growth fraction of human myeloma cells. Blood 57(2):333–338

    PubMed  CAS  Google Scholar 

  • Du J, Yang S, Wang Z, Zhai C, Yuan W, Lei R, Zhang J, Zhu T (2008) Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both smad and P38 pathways. J Cell Biochem 103(5):1584–1597

    Google Scholar 

  • Duan C (2002) Specifying the cellular responses to IGF signals: roles of IGF-binding proteins. J Endocrinol 175(1):41–54

    PubMed  CAS  Google Scholar 

  • Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K, Imamura T (1999) Characterization of bone morphogenetic protein-6 signaling pathways in osteoblast differentiation. J Cell Sci 112(Pt 20):3519–3527

    PubMed  CAS  Google Scholar 

  • Epstein J, Walker R (2006) Myeloma and bone disease: “the dangerous tango”. Clin Adv Hematol Oncol 4(4):300–306

    PubMed  Google Scholar 

  • Esteve FR, Roodman GD (2007) Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 20(4):613–624

    PubMed  CAS  Google Scholar 

  • Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, Kuchen S, Lipsky PE (2007) IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 178(5):2872–2882

    PubMed  CAS  Google Scholar 

  • Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M, Lai JL, Leleu X, Jouet JP, Bauters F, Harousseau JL, Bataille R, Mary JY (2001) Chromosome 13 abnormalities identified by FISH analysis and serum {beta}2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97(6):1566–1571

    PubMed  CAS  Google Scholar 

  • Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B (2000) Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway. Br J Haematol 111(2):626–634

    PubMed  CAS  Google Scholar 

  • Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B (1998) IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 161(6):2692–2699

    PubMed  CAS  Google Scholar 

  • Flactif M, Zandecki M, Lai JL, Bernardi F, Obein V, Bauters F, Facon T (1995) Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9(12):2109–2114

    PubMed  CAS  Google Scholar 

  • Fonseca R (2003) Many and multiple myeloma(s). Leukemia 17(10):1943–1944

    PubMed  CAS  Google Scholar 

  • Fonseca R, Oken MM, Greipp PR (2001a) The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood 98(4):1271–1272

    PubMed  CAS  Google Scholar 

  • Fonseca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van NB, Greipp PR, Dewald GW (2001b) Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy. Leukemia 15(6):981–986

    PubMed  CAS  Google Scholar 

  • Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR (2003a) Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101(11):4569–4575

    PubMed  CAS  Google Scholar 

  • Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Davila R, Gonzalez-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR (2003b) The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 102(7):2562–2567

    PubMed  CAS  Google Scholar 

  • Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, Hernandez JM, Minvielle S, Pilarski LM, Shaughnessy JD Jr, Stewart AK, Avet-Loiseau H (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64(4):1546–1558

    PubMed  CAS  Google Scholar 

  • Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B (1993) Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol 23(4):820–824

    PubMed  CAS  Google Scholar 

  • Gastinne T, Leleu X, Duhamel A, Moreau AS, Franck G, Andrieux J, Lai JL, Coiteux V, Yakoub-Agha I, Bauters F, Harousseau JL, Zandecki M, Facon T (2007) Plasma cell growth fraction using Ki-67 antigen expression identifies a subgroup of multiple myeloma patients displaying short survival within the ISS stage I. Eur J Haematol 79(4):297–304

    PubMed  CAS  Google Scholar 

  • Gautschi OP, Frey SP, Zellweger R (2007) Bone morphogenetic proteins in clinical applications. ANZ J Surg 77(8):626–631

    PubMed  Google Scholar 

  • Ge NL, Rudikoff S (2000) Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 96(8):2856–2861

    PubMed  CAS  Google Scholar 

  • Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K (1996) Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood 88(6):2250–2258

    PubMed  CAS  Google Scholar 

  • Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98(13):3527–3533

    PubMed  CAS  Google Scholar 

  • Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La MS, Bonomini S, Hojden M, Sammarelli G, Barille S, Bataille R, Rizzoli V (2002) Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100(13):4615–4621

    PubMed  CAS  Google Scholar 

  • Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, Grano M, Colucci S, Svaldi M, Rizzoli V (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106(7):2472–2483

    PubMed  CAS  Google Scholar 

  • Gonzalez-Garcia I, Rodriguez-Bayona B, Mora-Lopez F, Campos-Caro A, Brieva JA (2008) Increased survival is a selective feature of human circulating antigen-induced plasma cells synthesizing high-affinity antibodies. Blood 111(2):741–749

    PubMed  CAS  Google Scholar 

  • Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O’Fallon WM, Kyle RA (1987) Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 62(11):969–977

    PubMed  CAS  Google Scholar 

  • Greipp PR, Katzmann JA, O’Fallon WM, Kyle RA (1988) Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72(1):219–223

    PubMed  CAS  Google Scholar 

  • Greipp PR, Lust JA, O’Fallon WM, Katzmann JA, Witzig TE, Kyle RA (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81(12):3382–3387

    PubMed  CAS  Google Scholar 

  • Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B (1996) Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood 88(10):3972–3986

    PubMed  CAS  Google Scholar 

  • Haaber J, Abildgaard N, Knudsen LM, Dahl IM, Lodahl M, Thomassen M, Kerndrup GB, Rasmussen T (2008) Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 140(1):25–35

    PubMed  CAS  Google Scholar 

  • Hallek M, Bergsagel PL, Anderson KC (1998) Multiple myeloma: increasing evidence for a multistep transformation process. Blood 91(1):3–21

    PubMed  CAS  Google Scholar 

  • Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD Jr (2006) Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108(5):1724–1732

    PubMed  CAS  Google Scholar 

  • Harousseau JL, Moreau P (2009) Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 360(25):2645–2654

    PubMed  CAS  Google Scholar 

  • Hattinger CM, Potschger U, Tarkkanen M, Squire J, Zielenska M, Kiuru-Kuhlefelt S, Kager L, Thorner P, Knuutila S, Niggli FK, Ambros PF, Gadner H, Betts DR (2002) Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 86(11):1763–1769

    PubMed  CAS  Google Scholar 

  • Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F (2001) Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16(9):1575–1582

    PubMed  CAS  Google Scholar 

  • Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O (2006) Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 77(3):233–238

    PubMed  CAS  Google Scholar 

  • Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374(Pt 1):1–20

    PubMed  CAS  Google Scholar 

  • Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol 28(6):607–612

    PubMed  CAS  Google Scholar 

  • Hinson RM, Williams JA, Shacter E (1996) Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 93(10):4885–4890

    PubMed  CAS  Google Scholar 

  • Hjertner O, Torgersen ML, Seidel C, Hjorth-Hansen H, Waage A, Borset M, Sundan A (1999) Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease. Blood 94(11):3883–3888

    PubMed  CAS  Google Scholar 

  • Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A (2006) Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance. Blood 107(11):4484–4490

    PubMed  CAS  Google Scholar 

  • Hoechtlen-Vollmar W, Menzel G, Bartl R, Lamerz R, Wick M, Seidel D (2000) Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 109(1):30–38

    PubMed  CAS  Google Scholar 

  • Hose D, Rossi JF, Ittrich C, DeVos J, Benner A, Reme T, Bila J, Grau V, Raab M, Kaukel P, Jourdan E, Moos M, Theil AC, Jauch A, Goldschmidt H, Klein B, Cremer FW (2004) A new molecular classification of multiple myeloma using gene expression profiling and fluorescence in situ hybridisation as predictor for event free survival. ASH Ann Meeting Abstr 104(11):73

    Google Scholar 

  • Hose D, Rossi J-F, Ittrich C, DeVos J, Rème T, Benner A, Mahtouk K, del Val C, Moreaux J, Hotz-Wagenblatt A, Jonnakut S, Raab M, Kaukel P, Moos M, Grau V, Jauch A, Jourdan E, Cremere FW, Klein B, Goldschmidt H (2005) Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). Blood 106(111):150a

    Google Scholar 

  • Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Reme T, De VJ, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Mohler T (2009a) Induction of angiogenesis by normal and malignant plasma cells. Blood 114(1):128–143

    PubMed  CAS  Google Scholar 

  • Hose D, Reme T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Kramer A, Hillengass J, Bertsch U, Jauch A, De VJ, Rossi JF, Mohler T, Blake J, Zimmermann J, Klein B, Goldschmidt H (2009b) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113(18):4331–4340

    PubMed  CAS  Google Scholar 

  • Hose D, Reme T, Hielscher T, Moreaux J, Meissner T, Seckinger A, Benner A, Shaughnessy JD, Barlogie B, Zhou Y, Hillengass J, Bertsch U, Neben K, Mohler T, Rossi JF, Jauch A, Klein B, Goldschmidt H. (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96(1):87–95

    Google Scholar 

  • Hsu JH, Shi Y, Hu L, Fisher M, Franke TF, Lichtenstein A (2002) Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses. Oncogene 21(9):1391–1400

    PubMed  CAS  Google Scholar 

  • Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E, Grogan T, Bergsagel PL, Kuehl WM, Staudt LM (2004) Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5(2):191–199

    PubMed  CAS  Google Scholar 

  • Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Chaganti RS (2002) Molecular cytogenetic analysis of genomic instability at the 1q12-22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35(4):318–328

    PubMed  CAS  Google Scholar 

  • Jego G, Robillard N, Puthier D, Amiot M, Accard F, Pineau D, Harousseau JL, Bataille R, Pellat-Deceunynck C (1999) Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 94(2):701–712

    PubMed  CAS  Google Scholar 

  • Jelinek DF, Witzig TE, Arendt BK (1997) A role for insulin-like growth factor in the regulation of IL-6-responsive human myeloma cell line growth. J Immunol 159(1):487–496

    PubMed  CAS  Google Scholar 

  • Jonveaux P, Berger R (1992) Chromosome studies in plasma cell leukemia and multiple myeloma in transformation. Genes Chromosomes Cancer 4(4):321–325

    PubMed  CAS  Google Scholar 

  • Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B (1991) IFN-alpha induces autocrine production of IL-6 in myeloma cell lines. J Immunol 147(12):4402–4407

    PubMed  CAS  Google Scholar 

  • Jourdan M, De Vos J, Mechti N, Klein B (2000) Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 7(12):1244–1252

    PubMed  CAS  Google Scholar 

  • Jourdan M, Veyrune JL, De VJ, Redal N, Couderc G, Klein B (2003) A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 22(19):2950–2959

    PubMed  CAS  Google Scholar 

  • Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, Duperray C, De VJ, Klein B (2005) Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw 16(1):57–64

    PubMed  CAS  Google Scholar 

  • Jourdan M, Caraux A, De VJ, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D, Klein B (2009) An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 114(25):5173–5181

    PubMed  CAS  Google Scholar 

  • Kabashima K, Haynes NM, Xu Y, Nutt SL, Allende ML, Proia RL, Cyster JG (2006) Plasma cell S1P1 expression determines secondary lymphoid organ retention versus bone marrow tropism. J Exp Med 203(12):2683–2690

    PubMed  CAS  Google Scholar 

  • Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, McKenzie BS, Lew AM, Corcoran LM, Hodgkin PD, Tarlinton DM, Nutt SL (2007) Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity 26(5):555–566

    PubMed  CAS  Google Scholar 

  • Kawabata M, Imamura T, Miyazono K (1998) Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 9(1):49–61

    PubMed  CAS  Google Scholar 

  • Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332(6159):83–85

    PubMed  CAS  Google Scholar 

  • Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101(4):1520–1529

    PubMed  CAS  Google Scholar 

  • Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M, Lehenkari P (2005) In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 97(6):382–391

    PubMed  CAS  Google Scholar 

  • Kersten C, Sivertsen EA, Hystad ME, Forfang L, Smeland EB, Myklebust JH (2005) BMP-6 inhibits growth of mature human B cells; induction of Smad phosphorylation and upregulation of Id1. BMC Immunol 6(1):9

    PubMed  Google Scholar 

  • Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73(2):517–526

    PubMed  CAS  Google Scholar 

  • Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B (1991) Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78(5):1198–1204

    PubMed  CAS  Google Scholar 

  • Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF (2003) Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 78(2):106–113

    PubMed  CAS  Google Scholar 

  • Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, Vollmuth C, Falk K, Glasmacher A, Maeder U, Einsele H, Bargou RC (2009) Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 113(18):4137–4143

    PubMed  CAS  Google Scholar 

  • Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368(6469):339–342

    PubMed  CAS  Google Scholar 

  • Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2(3):175–187

    PubMed  CAS  Google Scholar 

  • Kunkel EJ, Butcher EC (2003) Plasma-cell homing. Nat Rev Immunol 3(10):822–829

    PubMed  CAS  Google Scholar 

  • Kuppers R, Dalla-Favera R (2001) Mechanisms of chromosomal translocations in B cell lymphomas. Oncogene 20(40):5580–5594

    PubMed  CAS  Google Scholar 

  • Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93(2):165–176

    PubMed  CAS  Google Scholar 

  • Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113(22):5412–5417

    PubMed  CAS  Google Scholar 

  • Latreille J, Barlogie B, Dosik G, Johnston DA, Drewinko B, Alexanian R (1980) Cellular DNA content as a marker of human multiple myeloma. Blood 55(3):403–408

    PubMed  CAS  Google Scholar 

  • Latreille J, Barlogie B, Johnston D, Drewinko B, Alexanian R (1982) Ploidy and proliferative characteristics in monoclonal gammopathies. Blood 59(1):43–51

    PubMed  CAS  Google Scholar 

  • Lattanzio G, Libert C, Aquilina M, Cappelletti M, Ciliberto G, Musiani P, Poli V (1997) Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. Am J Pathol 151(3):689–696

    PubMed  CAS  Google Scholar 

  • Le BP, Leroux D, Dascalescu C, Duley S, Marais D, Esmenjaud E, Sotto JJ, Callanan M (2001) Novel evidence of a role for chromosome 1 pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma. Genes Chromosomes Cancer 32(3):250–264

    Google Scholar 

  • Lewiecki EM (2006) RANK ligand inhibition with denosumab for the management of osteoporosis. Expert Opin Biol Ther 6(10):1041–1050

    PubMed  CAS  Google Scholar 

  • Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu KH, Li X, Richards WG (2006) Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39(4):754–766

    PubMed  CAS  Google Scholar 

  • Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P, Kyle RA, Oken MM, Van NB (1996) Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 88(7):2699–2706

    PubMed  CAS  Google Scholar 

  • Lokhorst HM, Boom SE, Bast BJ, Ballieux RE (1986) Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique. Br J Haematol 64(2):271–275

    PubMed  CAS  Google Scholar 

  • Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995a) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86(8):3123–3131

    PubMed  CAS  Google Scholar 

  • Lu ZY, Gu ZJ, Zhang XG, Wijdenes J, Neddermann P, Rossi JF, Klein B (1995b) Interleukin-10 induces interleukin-11 responsiveness in human myeloma cell lines. FEBS Lett 377(3):515–518

    PubMed  CAS  Google Scholar 

  • Lu YJ, Hing S, Williams R, Pinkerton R, Shipley J, Pritchard-Jones K (2002) Chromosome 1q expression profiling and relapse in Wilms’ tumour. Lancet 360(9330):385–386

    PubMed  CAS  Google Scholar 

  • Mackay F, Schneider P (2009) Cracking the BAFF code. Nat Rev Immunol 9(7):491–502

    PubMed  CAS  Google Scholar 

  • Magrangeas F, Lode L, Wuilleme S, Minvielle S, Avet-Loiseau H (2005) Genetic heterogeneity in multiple myeloma. Leukemia 19(2):191–194

    PubMed  CAS  Google Scholar 

  • Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B (2004) An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 103(5):1829–1837

    PubMed  CAS  Google Scholar 

  • Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi JF, Cremer FW, Klein B (2005) Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene 24(21):3512–3524

    PubMed  CAS  Google Scholar 

  • Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De VJ, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B (2006) Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene 25(54):7180–7191

    PubMed  CAS  Google Scholar 

  • Mahtouk K, Moreaux J, Hose D, Reme T, Meissner T, Jourdan M, Rossi JF, Pals ST, Goldschmidt H, Klein B (2010) Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 10:198

    PubMed  Google Scholar 

  • Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dorner T (2009) Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 113(11):2461–2469

    PubMed  CAS  Google Scholar 

  • Menoret E, Maiga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M (2008) IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol 181(10):6837–6842

    PubMed  CAS  Google Scholar 

  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC (2002) Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21(37):5673–5683

    PubMed  CAS  Google Scholar 

  • Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL, Bataille R, Avet-Loiseau H (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 100(5):1579–1583

    PubMed  CAS  Google Scholar 

  • Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K (2004) BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 103(8):3148–3157

    PubMed  CAS  Google Scholar 

  • Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 106(3):1021–1030

    PubMed  CAS  Google Scholar 

  • Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Mohler T, De VJ, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194–4197

    PubMed  CAS  Google Scholar 

  • Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, Robert N, Moine P, De VJ, Goldschmidt H, Klein B (2007) TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines. Haematologica 92(6):803–811

    PubMed  CAS  Google Scholar 

  • Moreaux J, Sprynski AC, Dillon SR, Mahtouk K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, Klein B (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83(2):119–129

    PubMed  CAS  Google Scholar 

  • Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams PJ, Mundy GR, Yoneda T (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104(7):2149–2154

    PubMed  CAS  Google Scholar 

  • Murray AW (2004) Recycling the cell cycle: cyclins revisited. Cell 116(2):221–234

    PubMed  CAS  Google Scholar 

  • Nagasawa T (2006) Microenvironmental niches in the bone marrow required for B-cell development. Nat Rev Immunol 6(2):107–116

    PubMed  CAS  Google Scholar 

  • Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Muller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H (2010) Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 95(7):1150–1157

    PubMed  CAS  Google Scholar 

  • Neri A, Murphy JP, Cro L, Ferrero D, Tarella C, Baldini L, Dalla-Favera R (1989) Ras oncogene mutation in multiple myeloma. J Exp Med 170(5):1715–1725

    PubMed  CAS  Google Scholar 

  • Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S, Kodama H (1999) Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190(2):293–298

    PubMed  CAS  Google Scholar 

  • Nishida K, Tamura A, Nakazawa N, Ueda Y, Abe T, Matsuda F, Kashima K, Taniwaki M (1997) The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90(2):526–534

    PubMed  CAS  Google Scholar 

  • Nohe A, Keating E, Knaus P, Petersen NO (2004) Signal transduction of bone morphogenetic protein receptors. Cell Signal 16(3):291–299

    PubMed  CAS  Google Scholar 

  • Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103(2):689–694

    PubMed  CAS  Google Scholar 

  • Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33(3):272–278

    PubMed  CAS  Google Scholar 

  • Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, Berek C, Hiepe F, Manz R, Radbruch A, Dorner T (2005) Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105(4):1614–1621

    PubMed  CAS  Google Scholar 

  • Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D, Matsumoto T (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106(9):3160–3165

    PubMed  CAS  Google Scholar 

  • Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, Morse HC III, Liu C, Schwartzberg PL, Leonard WJ (2002) A critical role for IL-21 in regulating immunoglobulin production. Science 298(5598):1630–1634

    PubMed  CAS  Google Scholar 

  • Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y (2001) Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98(20):11581–11586

    PubMed  CAS  Google Scholar 

  • Pene F, Claessens YE, Muller O, Viguie F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D (2002) Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 21(43):6587–6597

    PubMed  CAS  Google Scholar 

  • Pfeffer LM, Mullersman JE, Pfeffer SR, Murti A, Shi W, Yang CH (1997) STAT3 as an adapter to couple phosphatidylinositol 3-kinase to the IFNAR1 chain of the type I interferon receptor. Science 276(5317):1418–1420

    PubMed  CAS  Google Scholar 

  • Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A (2004) Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126(5):686–689

    PubMed  CAS  Google Scholar 

  • Portier M, Rajzbaum G, Zhang XG, Attal M, Rusalen C, Wijdenes J, Mannoni P, Maraninchi D, Piechaczyk M, Bataille R (1991) In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 21(7):1759–1762

    PubMed  CAS  Google Scholar 

  • Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, Bataille R, Amiot M (1999) Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol 107(2):392–395

    PubMed  CAS  Google Scholar 

  • Qiang YW, Kopantzev E, Rudikoff S (2002) Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk. Blood 99(11):4138–4146

    PubMed  CAS  Google Scholar 

  • Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 6(10):741–750

    PubMed  CAS  Google Scholar 

  • Reece D, Song KW, Fu T, Roland B, Chang H, Horsman DE, Mansoor A, Chen C, Masih-Khan E, Trieu Y, Bruyere H, Stewart DA, Bahlis NJ (2009) Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood 114(3):522–525

    PubMed  CAS  Google Scholar 

  • Reijmers RM, Groen RW, Rozemuller H, Kuil A, de Haan-Kramer A, Csikos T, Martens AC, Spaargaren M, Pals ST (2010) Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma. Blood 115(3):601–604

    PubMed  CAS  Google Scholar 

  • Ren R, Charles PC, Zhang C, Wu Y, Wang H, Patterson C (2007) Gene expression profiles identify a role for cyclooxygenase 2-dependent prostanoid generation in BMP6-induced angiogenic responses. Blood 109(7):2847–2853

    PubMed  CAS  Google Scholar 

  • Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blade J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487–2498

    PubMed  CAS  Google Scholar 

  • Ro TB, Holt RU, Brenne AT, Hjorth-Hansen H, Waage A, Hjertner O, Sundan A, Borset M (2004) Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23(17):3024–3032

    PubMed  Google Scholar 

  • Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, Kaminski M, Simeone J, Seaman J, Chen BL, Coleman RE (2004) Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 100(1):36–43

    PubMed  CAS  Google Scholar 

  • Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185–197

    PubMed  CAS  Google Scholar 

  • Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouille V, Kanouni T, Widjenes J, Klein B (2005) Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant 36(9):771–779

    PubMed  CAS  Google Scholar 

  • Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouille V, Nestorov I, Mordenti G, Goldschmidt H, Ythier A, Klein B (2009) Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom’s macroglobulinemia: a phase I study. Br J Cancer 101(7):1051–1058

    PubMed  Google Scholar 

  • Saito M, Gao J, Basso K, Kitagawa Y, Smith PM, Bhagat G, Pernis A, Pasqualucci L, Della-Favera R (2007) A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell 12(3):280–292

    PubMed  CAS  Google Scholar 

  • San Miguel JF, Garcia-Sanz R, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R (1995) A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85(2):448–455

    PubMed  CAS  Google Scholar 

  • San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359(9):906–917

    PubMed  CAS  Google Scholar 

  • Sanderson RD, Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25(2):149–159

    PubMed  CAS  Google Scholar 

  • Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr (2003) A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood 101(6): 2374–2376

    PubMed  CAS  Google Scholar 

  • Schambeck CM, Wick M, Bartl R, Lamerz R, Fateh-Moghadam A (1995) Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase. J Clin Pathol 48(5):477–481

    PubMed  CAS  Google Scholar 

  • Schmidlin H, Diehl SA, Blom B (2009) New insights into the regulation of human B-cell differentiation. Trends Immunol 30(6):277–285

    PubMed  CAS  Google Scholar 

  • Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Reme T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De VJ, Rossi JF, Mohler T, Klein B, Hose D (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28(44):3866–3879

    PubMed  CAS  Google Scholar 

  • Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A (1998) Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 91(3):806–812

    PubMed  CAS  Google Scholar 

  • Sezer O, Heider U, Jakob C, Eucker J, Possinger K (2002) Human bone marrow myeloma cells express RANKL. J Clin Oncol 20(1):353–354

    PubMed  Google Scholar 

  • Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS (2009) Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69(3):1009–1015

    PubMed  CAS  Google Scholar 

  • Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109(6):2276–2284

    PubMed  CAS  Google Scholar 

  • Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672–1677

    PubMed  CAS  Google Scholar 

  • Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512

    PubMed  CAS  Google Scholar 

  • Sherr CJ, Roberts JM (2004) Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18(22):2699–2711

    PubMed  CAS  Google Scholar 

  • Shipman CM, Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63(5):912–916

    PubMed  CAS  Google Scholar 

  • Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ (2002) A molecular study of the t(4;14) in multiple myeloma. Br J Haematol 118(2):514–520

    PubMed  CAS  Google Scholar 

  • Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89(2):309–319

    PubMed  CAS  Google Scholar 

  • Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C (2001) Hypodiploidy is a major prognostic factor in multiple myeloma. Blood 98(7):2229–2238

    PubMed  CAS  Google Scholar 

  • Specht K, Haralambieva E, Bink K, Kremer M, Mandl-Weber S, Koch I, Tomer R, Hofler H, Schuuring E, Kluin PM, Fend F, Quintanilla-Martinez L (2004) Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 104(4):1120–1126

    PubMed  CAS  Google Scholar 

  • Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113(19):4614–4626

    PubMed  CAS  Google Scholar 

  • Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C (2002) Serum insulin like growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 100(12):3925–3929

    PubMed  CAS  Google Scholar 

  • Standal T, Abildgaard N, Fagerli UM, Stordal B, Hjertner O, Borset M, Sundan A (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109(7):3024–3030

    PubMed  CAS  Google Scholar 

  • Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 86(19):7547–7551

    PubMed  CAS  Google Scholar 

  • Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1992) Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 89(1):232–235

    PubMed  CAS  Google Scholar 

  • Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 63(18):5850–5858

    PubMed  CAS  Google Scholar 

  • Tanaka Y, Abe M, Hiasa M, Oda A, Amou H, Nakano A, Takeuchi K, Kitazoe K, Kido S, Inoue D, Moriyama K, Hashimoto T, Ozaki S, Matsumoto T (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13(3):816–823

    PubMed  CAS  Google Scholar 

  • Tarlinton D, Radbruch A, Hiepe F, Dorner T (2008) Plasma cell differentiation and survival. Curr Opin Immunol 20(2):162–169

    PubMed  CAS  Google Scholar 

  • Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA (1992) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49(4):192–198

    PubMed  CAS  Google Scholar 

  • Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A (2003a) Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123(1): 106–109

    PubMed  CAS  Google Scholar 

  • Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A (2003b) Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102(3):1064–1069

    PubMed  CAS  Google Scholar 

  • Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD Jr (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349(26):2483–2494

    PubMed  CAS  Google Scholar 

  • Tienhaara A, Pelliniemi TT (1992) Flow cytometric DNA analysis and clinical correlations in multiple myeloma. Am J Clin Pathol 97(3):322–330

    PubMed  CAS  Google Scholar 

  • Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T (2004) Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20(6):707–718

    PubMed  CAS  Google Scholar 

  • Trojan A, Tinguely M, Vallet S, Seifert B, Jenni B, Zippelius A, Witzens-Harig M, Mechtersheimer G, Ho A, Goldschmidt H, Jager D, Boccadoro M, Ladetto M (2006) Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly 136(25–26):400–403

    PubMed  CAS  Google Scholar 

  • Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38(12):1424–1429

    PubMed  CAS  Google Scholar 

  • Tu Y, Gardner A, Lichtenstein A (2000) The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res 60(23):6763–6770

    PubMed  CAS  Google Scholar 

  • Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 82(12):3712–3720

    PubMed  CAS  Google Scholar 

  • Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME (1982) Quantitative histology of myeloma-induced bone changes. Br J Haematol 52(4):601–610

    PubMed  CAS  Google Scholar 

  • von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21(9):2025–2034

    Google Scholar 

  • Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF, Klein B (2002) Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene 21(16): 2584–2592

    PubMed  CAS  Google Scholar 

  • Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, Laurent P, Sun RX, Klein B, Dore JM (1996) A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 94(2):318–323

    PubMed  CAS  Google Scholar 

  • Witzig TE, Timm M, Larson D, Therneau T, Greipp PR (1999) Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol 104(1):131–137

    PubMed  CAS  Google Scholar 

  • Wlodarska I, Meeus P, Stul M, Thienpont L, Wouters E, Marcelis L, Demuynck H, Rummens JL, Madoe V, Hagemeijer A (2004) Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. Leukemia 18(10):1705–1710

    PubMed  CAS  Google Scholar 

  • Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL, Proffitt J, Minvielle S, Avet-Loiseau H (2005) Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19(2):275–278

    PubMed  CAS  Google Scholar 

  • Wutzl A, Brozek W, Lernbass I, Rauner M, Hofbauer G, Schopper C, Watzinger F, Peterlik M, Pietschmann P (2006) Bone morphogenetic proteins 5 and 6 stimulate osteoclast generation. J Biomed Mater Res A 77(1):75–83

    PubMed  Google Scholar 

  • Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64(6):2016–2023

    PubMed  CAS  Google Scholar 

  • Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD Jr (2007) Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109(5):2106–2111

    PubMed  CAS  Google Scholar 

  • Yamasaki K, Taga T, Hirata Y, Yawata H, Kawanishi Y, Seed B, Taniguchi T, Hirano T, Kishimoto T (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241(4867):825–828

    PubMed  CAS  Google Scholar 

  • Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr (2002) Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99(5):1745–1757

    PubMed  CAS  Google Scholar 

  • Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr (2006) The molecular classification of multiple myeloma. Blood 108(6):2020–2028

    PubMed  CAS  Google Scholar 

  • Zhang XG, Bataille R, Widjenes J, Klein B (1992) Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer 69(6):1373–1376

    PubMed  CAS  Google Scholar 

  • Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B (1994a) Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83(12):3654–3663

    PubMed  CAS  Google Scholar 

  • Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R et al (1994b) Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 179(4):1337–1342

    PubMed  CAS  Google Scholar 

  • Zudaire I, Odero MD, Caballero C, Valenti C, Martinez-Penuela JM, Isola J, Calasanz MJ (2002) Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 40(6):547–555

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the Ligue Nationale Contre le Cancer (équipe labellisée 2009), France, from INCA (PL06_070), the Hopp-Foundation, Germany, and the Deutsche Forschungsgemeinschaft (DFG) Transregio TRR79, Germany.

Author information

Authors and Affiliations

  1. Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Dirk Hose

  2. National Center for Tumor Diseases, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany

    Dirk Hose

Authors
  1. Bernard Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anja Seckinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Moehler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dirk Hose
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Hose .

Editor information

Editors and Affiliations

  1. Medizinische Klinik und Poliklinik, Abt. Hämatologie, Onkologie und, Universitätsklinikum Heidelberg, Hospitalstr. 3, Heidelberg, 69115, Germany

    Thomas Moehler

  2. Medizinische Klinik und Poliklinik, Abt. Innere Medizin V, Universitätsklinikum Heidelberg, Hospitalstr. 3, Heidelberg, 69115, Germany

    Hartmut Goldschmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Klein, B., Seckinger, A., Moehler, T., Hose, D. (2011). Molecular Pathogenesis of Multiple Myeloma: Chromosomal Aberrations, Changes in Gene Expression, Cytokine Networks, and the Bone Marrow Microenvironment. In: Moehler, T., Goldschmidt, H. (eds) Multiple Myeloma. Recent Results in Cancer Research, vol 183. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85772-3_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-85772-3_3

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-85771-6

  • Online ISBN: 978-3-540-85772-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation